# ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial

> **NCT00772902** · PHASE4 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 85 (actual)

## Conditions studied

- HIV-1

## Interventions

- **DRUG:** Truvada + Kaletra
- **DRUG:** Kivexa + Kaletra

## Key facts

- **NCT ID:** NCT00772902
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2009-09
- **Final completion:** 2009-10
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2011-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00772902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00772902, "ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00772902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*